Wanbury Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 4/6
Wanbury has been growing earnings at an average annual rate of 15.6%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 9.9% per year. Wanbury's return on equity is 187.2%, and it has net margins of 9.3%.
Key information
15.6%
Earnings growth rate
10.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 9.9% |
| Return on equity | 187.2% |
| Net Margin | 9.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Wanbury makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 5,605 | 523 | 910 | 0 |
| 31 Mar 24 | 5,756 | 560 | 979 | 0 |
| 31 Dec 23 | 5,692 | 233 | 933 | 0 |
| 30 Sep 23 | 5,495 | 98 | 879 | 0 |
| 30 Jun 23 | 5,290 | 15 | 806 | 0 |
| 31 Mar 23 | 4,996 | -104 | 869 | 0 |
| 31 Dec 22 | 5,011 | 711 | 865 | 0 |
| 30 Sep 22 | 5,001 | 748 | 868 | 0 |
| 30 Jun 22 | 5,003 | 751 | 778 | 0 |
| 31 Mar 22 | 5,112 | 815 | 831 | 0 |
| 31 Dec 21 | 4,972 | -100 | 766 | 0 |
| 30 Sep 21 | 4,821 | -45 | 729 | 0 |
| 30 Jun 21 | 4,532 | -23 | 708 | 0 |
| 31 Mar 21 | 3,925 | -126 | 692 | 0 |
| 31 Dec 20 | 3,391 | 587 | 756 | 0 |
| 30 Sep 20 | 3,264 | 507 | 767 | 0 |
| 30 Jun 20 | 3,406 | 541 | 774 | 0 |
| 31 Mar 20 | 3,675 | 645 | 795 | 0 |
| 31 Dec 19 | 4,020 | -78 | 867 | 0 |
| 30 Sep 19 | 4,099 | -79 | 893 | 0 |
| 30 Jun 19 | 3,997 | -171 | 738 | 0 |
| 31 Mar 19 | 3,914 | -248 | 937 | 0 |
| 31 Mar 18 | 3,711 | -320 | 1,068 | 0 |
| 31 Mar 17 | 4,338 | 620 | 1,114 | 0 |
| 31 Mar 16 | 4,233 | -71 | 1,087 | 0 |
| 31 Mar 15 | 4,998 | 64 | 943 | 0 |
| 30 Sep 14 | 4,412 | -851 | 1,493 | 0 |
Quality Earnings: 524212 has a large one-off gain of ₹255.6M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: 524212's current net profit margins (9.3%) are higher than last year (0.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524212 has become profitable over the past 5 years, growing earnings by 15.6% per year.
Accelerating Growth: 524212's earnings growth over the past year (3302.6%) exceeds its 5-year average (15.6% per year).
Earnings vs Industry: 524212 earnings growth over the past year (3302.6%) exceeded the Pharmaceuticals industry 19.2%.
Return on Equity
High ROE: Whilst 524212's Return on Equity (187.2%) is outstanding, this metric is skewed due to their high level of debt.